Jaume Alijotas Reig Institutions of which they are part Head of group Systemic Diseases Vall Hebron Institut de Recerca Email Jaume Alijotas Reig Email Institutions of which they are part Head of group Systemic Diseases Vall Hebron Institut de Recerca
Research lines Cellular microparticles study in women with and without antiphospholipid antibodies with recurrent pregnancy loses and preeclampsia. Cellular microparticles (CMP) are released depending on the activation and/or the presence of cell apoptosis. They are capable of activating both inflammatory and coagulation pathways. It seems that levels of CMP are higher in healthy pregnant women. A working hypothesis establishes that an increase of CMP levels may be found in recurrent pregnancy loses and preeclampsia. It is thought that their thrombophilic capacity may be higher in those patients with anti-phospholipid antibodies, especially among those with lupus anticoagulant. We want to determine MPC levels in non-pregnant healthy women, pregnant women without previous abnormal obstetric events, women with recurrent pregnancy loses, and women with severe preeclampsia. We are also evaluating whether there are differences related to the presence or absence of antiphospholipid antibodies. Finally, we will also characterize the exact type of CMP (endothelial, platelet-like, leuco-monocyte, and throphoblastic). IP: Jaume Alijotas Reig Pathogenic role of cellular microparticles and anti-phospholipid/anti-cofactor antibodies in recurrent implantation failures related to In Vitro Fertilization (IVF). The prevalence of failed IVF is high or very high. Besides problems intrinsic to the technique, we know almost nothing about the possible underlying causes. Anti-phospholipid/anti-cofactor (aPL/aCF) antibodies have been associated to several obstetric complications. Nevertheless, the role that these aPL/aCF antibodies may have in failed IVF is not well defined. With this randomized study we want to understand better the use that these antibodies may have on a clinical daily basis. Along with the microparticles analysis, we could end up by finding several elements that might act as risk markers; in turn, it might even help us to fine-tune the currently used therapeutic approaches. IP: Jaume Alijotas Reig Pagination First page « Previous page ‹ Page 1 Page 2 Current page 3 Projects GLOBE: Gestación Ligada a Obesidad y al Entorno. Estudio longitudinal multicéntrico de factores de riesgo asociados a la obesidad en el embarazo IP: - Collaborators: Jaume Alijotas Reig, Inés Zulema Calero Fernández, Maite Avilés García Funding agency: Instituto de Salud Carlos III Funding: 135883 Reference: PI10/01367 Duration: 01/01/2011 - 31/12/2014 Heparina de Bajo Peso Molecular (HBPM) para la prevención de complicaciones derivadas de la insuficiencia placentaria en las pacientes de riesgo sin trombofilia: estudio multicéntrico randomizado IP: - Collaborators: Jaume Alijotas Reig, Inés Zulema Calero Fernández, Elisa Llurba Olivé, Josep Perapoch López Funding agency: Ministerio Sanidad Funding: 80000 Reference: EC10-205 Duration: 01/01/2011 - 31/12/2016 Envejecimiento endotelial y sus efectos pleiotrópicos sobre procesos inflamatorios, de la respuesta inmune y angiogénesis IP: Francesc Miro Mur Collaborators: Jaume Alijotas Reig, Simon Schwartz Navarro Funding agency: Fundación Invest. Médica Mutua Madrileña Funding: 36000 Reference: FMMA/05/2008 Duration: 24/09/2008 - 23/09/2011 CIBER: Bioingenieria, biomateriales y nanomedicina IP: - Collaborators: Manuel López Cano, Jaume Alijotas Reig, Francesc Miro Mur, Eloy Espín Basany Funding agency: CIBER Bioing., Biomateriales y Nanomedicina , BBN Funding: 480000 Reference: CB06/01/0012 Duration: 01/01/2007 - 31/12/2010 Pagination First page « Previous page ‹ Page 1 Page 2 Current page 3
